ArticleBMC cancer2020

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.

Masaaki Miyo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.